BIIB News 285.81 04/28/2014 05:03:55 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 285.81 $BIIB

Can Biogen Dethrone Baxter in Hemophilia?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 25, 5:30PM CDT
Drugmakers like Biogen are enjoying a new wave of success as they usher next-generation therapies to market that are displacing prior treatments. Gilead has de-throned injectible drugs as the standard of care with a faster and better working...

SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 3.06% Loss
Comtex SmarTrend(R) - Fri Apr 25, 4:01PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $285.58 to a high of $296.74. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $286.48 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Watch for Biogen Idec to Potentially Rebound After Falling 3.06% Yesterday
Comtex SmarTrend(R) - Fri Apr 25, 4:00PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $285.58 to a high of $296.74. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $286.48 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

PharmaPoint: Crohn's Disease - Current and Future Players
M2 - Fri Apr 25, 9:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4n3bcj/pharmapoint) has announced the addition of the "PharmaPoint: Crohn's Disease - Current and Future Players" report to their offering. PharmaPoint: Crohn's Disease - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Crohn's Disease Market. The report identifies and analyses the key companies shaping and driving the global Crohn's Disease market. The report provides insight into the competitive Crohn's Disease landscape, including new companies entering the market. Scope - Investigation of current and future market competition for Crohn's Disease - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Crohn's Disease sector through market impact analysis, future market scenario and company analysis Key Topics Covered: - Tables & Figures - Introduction - Market Outlook - Current and Future Players - Appendix Companies Mentioned - Johnson & Johnson - AbbVie - UCB - Biogen Idec - Takeda - ChemoCentryx For more information visit http://www.researchandmarkets.com/research/4n...harmapoint

Quintiles enters into comprehensive clinical development partnership with Biogen Idec
M2 - Fri Apr 25, 6:01AM CDT
Biopharmaceutical company Quintiles revealed on Thursday the launch of a multi year strategic clinical development agreement with Biogen Idec (NasdaqGS:BIIB).

Why Xilinx Inc., Biogen Idec Inc., and Qualcomm Incorporated Are Today’s 3 Worst Stocks
John Divine, The Motley Fool - Motley Fool - Thu Apr 24, 7:04PM CDT
U.S. manufacturers are starting to hit their strides this spring, according to new data from the Census Bureau. Durable goods orders rose 2.6% in March from February, notably better than the 2% increase expected by Econoday; the strong demand is a...

Why Investors Should Love Biogen's Earnings Miss
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Big biotech  Biogen Idec has weathered the industry's storm in a rocky 2014. The stock's gained more than 9% despite the biotech sector's fall brought on by nervous investors concerned about the market's rally, and Biogen has plenty of room for...

Spectrum Pharma Candidate Gets Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:50PM CDT
Spectrum Pharmaceuticals (SPPI) announced encouraging results from a phase II pivotal study on captisol-enabled melphalan.

Stock Market News for April 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 9:06AM CDT
Benchmarks ended lower on Wednesday following disappointing corporate results and economic data

Earnings Roundup: Biogen's Tecfidera Wins More Share
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 24, 8:30AM CDT
Biogen remains a market leader in treating multiple sclerosis, an autoimmune disease that affects more than 1.1 million people in the U.S. and Europe. The company has launched a host of widely successful MS therapies over the past decade,...

Ambit Biosciences Slumps: AMBI Falls 7.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:49AM CDT
Ambit Biosciences saw a big move last session, as the company’s shares fell by over 7% on the day

Prothena Corporation plc (PRTA) Worth Watching: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:44AM CDT
Prothena Corporation plc (PRTA) was a big mover last session, as the company saw its shares rally nearly 10.00% on the day.

Quintiles and Biogen Idec Announce Comprehensive Clinical Development Partnership
Business Wire - Thu Apr 24, 7:00AM CDT
Quintiles, the world's largest provider of biopharmaceutical development and commercial outsourcing services, and Biogen Idec (NASDAQ: BIIB) have entered into a five-year strategic clinical development agreement. The multi-year collaboration is designed to leverage the expertise and experience from both organizations to optimize Biogen Idec's clinical development processes.

Biogen EPS misses, guides up
at Investor's Business Daily - Wed Apr 23, 5:49PM CDT
The biotech's Q1 EPS jumped 25% to $2.47, but missed views by 9 cents. Revenue rose 50.5% to $2.13 bil, above views for $2 bil. U.S. sales of MS drug Tecfidera were $460 mil vs. views of $413 mil. Nearly all individual product sales beat consensus....

Biogen Q1, Guidance Strong
at Investor's Business Daily - Wed Apr 23, 5:46PM CDT
Big-cap biotech Biogen Idec reported solid Q1 revenue early Wednesday and guided 2014 above Wall Street's expectations, but the stock rose just a fraction as biotechs had a bad day and Biogen revealed it's being probed by authorities. Biogen (BIIB)...

Why Biogen (BIIB) Stock Is Down Today
at The Street - Wed Apr 23, 12:55PM CDT
Biogen (BIIB) shares fall as Biotech ETF as takes a hit in trading today

Biogen's Q1 Earnings Soar Y/Y on Tecfidera Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 12:40PM CDT
Although Biogen (BIIB) missed earnings estimates, revenues surpassed expectations easily. The company also raised its guidance.

Interesting BIIB Put And Call Options For June 21st
at The Street - Wed Apr 23, 10:05AM CDT
Investors in Biogen Idec Inc saw new options begin trading this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options chain for the new June 21st contracts and identified one put...

Biogen Q1 Sales Beat Street, Guidance Strong
at Investor's Business Daily - Wed Apr 23, 9:11AM CDT
Big-cap biotech Biogen Idec (BIIB) reported solid Q1 revenue early Wednesday and guided 2014 above Wall Street's expectations, but the stock was down more than 1% in early trading in the stock market today. Biogen said revenue rose 50.5% over the...

Amgen's Q1 Earnings Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 8:40AM CDT
Amgen's first quarter results were disappointing with most of the products recording a sequential decline in sales.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 108

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
A Teen's Opera Encounter Inspires Decades of Passion

Updated Category News Views 58

Unraveling a Lifelong Opera Obsession Back in the dog-eared days of 1970, a teenager waltzed into the Metropolitan Opera and stumbled onto a passion that'd pulse alongside him for over half a century. Now, David E. Lapin rolls out his personal chronicle, 'A Sound Obsession: Fifty-Five Years of Opera at the Met.' Folks, we’re diving into a cultural tapestry that’s...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 57

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 122

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 39

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Rock & Roll Hall of Fame's 2026 Induction Triumph

Updated Category News Views 90

A Night of Unstoppable Talent The Rock & Roll Hall of Fame's 2026 Induction Ceremony and boy, what a spectacle it was. Held on a lively Saturday night, November 14, in Los Angeles, it wasn't just an event; it was an electrifying testament to music's profound impact. With the grand ceremony kicking off at the historic city of stars, this year's induction turned the dial to...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 17

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 94

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 39

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading

Top 5 Most Recently Viewed Articles

Warren Buffett's Wisdom: Rethinking Your Stock Strategy

Updated Category News Views 155

Billionaire investor Warren Buffett became a titan in finance through his distinctive approach to stock investing, one that flips conventional wisdom on its head. While most folks lose their heads when prices drop, Buffett sees opportunity. When stocks go down, he doesn’t cry; he gets excited. "I love it when the things we buy go down," he said in a reflective moment...

Continue Reading
Kenneth L Calloway's $452K Share Sale: What It Means for CENX

Updated Category News Views 220

Understanding the Recent Insider Trade in Century Aluminum In a notable move that has caught the attention of investors, Kenneth L Calloway, the Senior Vice President at Century Aluminum, recently sold a significant amount of stocks. The transaction, which took place recently and is detailed in an SEC filing, involved the sale of 16,450 shares valued at approximately...

Continue Reading
Jura Energy Corporation Releases Key Financial Information

Updated Category News Views 213

Jura Energy Corporation Financial Filings Overview Jura Energy Corporation has recently announced an important update regarding its financial performance. The company has filed its condensed consolidated interim financial statements for the periods ending June 30 for both 2025 and 2024 on SEDAR. Alongside these financial statements, Jura has also released its...

Continue Reading
Exploring the Surge in Edge Computing Growth and Its Impact

Updated Category News Views 207

Understanding Edge Computing Growth Dynamics The edge computing market is poised for significant growth, projected to increase by USD 19.6 billion during the period between 2024 and 2028. This advancement is primarily fueled by the rising demand for decentralized computing, aimed at minimizing latency in decision-making processes. Technological advancements heralding...

Continue Reading
Hiab's Q3 Report 2025: Navigating Challenges with Resilience

Updated Category News Views 239

Hiab's Financial Journey in Q3 2025: An Overview Hiab's latest quarterly report sheds light on the company's performance amidst swirling market uncertainties. The recent challenges stemmed primarily from lower sales figures in parts of their market, particularly in the United States, affecting profitability. Key Highlights of the Quarterly Performance The first major...

Continue Reading